Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States

The information in the brief version is excerpted directly from the full-text guidelines. The brief version is a compilation of the tables and boxed recommendations.

  •   Table of Contents

Download Guidelines

Non-Nucleoside Reverse Transcriptase Inhibitors

Doravirine (Pifeltro, DOR)

Last Updated: December 7, 2018; Last Reviewed: December 7, 2018

Excerpt from Table 10a

Note: When using FDCs, refer to other sections in Appendix B and Table 10 for information about the dosing and safety of individual drug components of the FDC during pregnancy.

Generic Name
(Abbreviation)
Trade Name
Formulation Dosing Recommendations Use in Pregnancy
Doravirine
(DOR)
Pifeltro

(DOR/3TC/TDF)
Delstrigo
DOR (Pifeltro):
  • 100 mg tablet
DOR/3TC/TDF (Delstrigo):
  • DOR 100 mg plus 3TC 300 mg plus TDF 300 mg tablet
Standard Adult Doses
DOR (Pifeltro):
  • 100 mg once daily with or without food
DOR/3TC/TDF (Delstrigo):
  • 1 tablet once daily with or without food
PK in Pregnancy:
  • No PK studies in human pregnancy.
Dosing in Pregnancy:
  • Insufficient data to make dosing recommendation.
For guidance about use of combination products in pregnancy, please see the specific sections on other components (i.e., 3TC, TDF)
No human data are available on placental transfer of DOR, but animal studies suggest that DOR crosses the placenta.

Insufficient data to assess for teratogenicity in humans. No evidence of teratogenicity in rats or rabbits.
a Individual ARV drug doses may need to be adjusted in patients with renal or hepatic insufficiency (for details, see the Adult and Adolescent Guidelines, Appendix B, Table 8).

Key to Acronyms: 3TC = lamivudine; ARV = antiretroviral; DOR = doravirine; FDC = fixed-dose combination; PK = pharmacokinetic; TDF = tenofovir disoproxil fumarate

Download Guidelines